Abstract
Colchicine is a frequently used drug in rheumatological diseases. Acute promyelocytic leukemia developed in a patient who used colchicine for gouty arthritis since 10 years is presented and the possible relation between the long term use of colchicine and hematological malignancies is discussed.
References
Ozdogu H, Boga C, Yılmaz Z, Sahin FI, Bal N (2007) Long-term colchicine therapy in a patient with Behçet’s disease and acute promyelocytic leukemia. Rheumatol Int 27:763–765
Kuo CF, Luo SF, See LC, Chou IJ, Fang YF, Yu KH (2012) Increased risk of c ancer among gout patients; a nationwide population study. Joint Bone Spine 79(4):375–378
Ramadan SM, Fouad TM, Summa V, Hasan SKH, Lo-Coco F (2012) Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 97:805–817
Krishnan E, Chen L (2013) Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009. Arthritis Res Ther 15:R181
Bryce SM, Avlasevich SL, Bemis JC, Phonethepswath S, Dertinger SD (2010) Miniaturized flow cytometric in vitro micronucleus assay represents an efficient tool for comprehensively characterizing genotoxicity dose-response relationships. Mutat Res 703:191–199
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buyukkurt, N., Korur, A. & Boga, C. Development of Acute Promyelocytic Leukemia in a Patient With Gouty Arthritis on Long Term Colchicine. Indian J Hematol Blood Transfus 32 (Suppl 1), 80–81 (2016). https://doi.org/10.1007/s12288-015-0523-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-015-0523-4